BLADDER CANCER: Edited by Siamak DaneshmandPerioperative systemic therapy for bladder cancerEulitt, Patrick J.a; Bjurlin, Marc A.b,c; Milowsky, Matthew I.a,cAuthor Information aDivision of Hematology/Oncology, Department of Medicine bDepartment of Urology cLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA Correspondence to Matthew I. Milowsky, MD, Division of Hematology/Oncology, Department of Medicine, University of North Carolina, 170 Manning Drive, CB #7305, Chapel Hill, NC 27599, USA. Tel: +1 919 843 7942; fax: +1 919 966 6735; e-mail: firstname.lastname@example.org Current Opinion in Urology: May 2019 - Volume 29 - Issue 3 - p 220-226 doi: 10.1097/MOU.0000000000000600 Buy Metrics Abstract Purpose of review Recent advances in research related to biomarkers and immunotherapy has the potential to transform the landscape for the use of perioperative systemic therapy in patients with bladder cancer. Recent findings Predictive biomarkers including DNA damage repair genes and gene expression profiling may soon lead to better selection of patients for neoadjuvant cisplatin-based chemotherapy. Success of immunotherapy for the treatment of metastatic bladder cancer has led to promising trials exploring immunotherapy in muscle-invasive disease. Summary Current trials employing predictive biomarkers as well as those using immunotherapy have the potential to significantly improve the outcome of patients with muscle-invasive bladder cancer. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.